Literature DB >> 3403994

Estimating the dosage of ribavirin aerosol according to age and other variables.

V Knight1, C P Yu, B E Gilbert, G W Divine.   

Abstract

We describe a method for estimating the dosage of aerosolized ribavirin according to age. The calculations were determined by using a computer model of particle deposition, and corrections are described for sex, body weight, fever, and tracheal intubation. Respiratory tract deposition in infants, after they inhaled an aerosol containing 200 micrograms of ribavirin/L, was 1.8 mg/kg per hour; in adults the deposition was 0.9 mg/kg per hour. Adolescent females and older women have less (7%/kg) respiratory tract deposition than do males. Fever will increase deposition about 9%/degree Centigrade (5%/degree Fahrenheit) for each degree of increase above normal temperature. Tracheal intubation will deliver relatively more drug to the lung and no drug to the nasopharynx. Our report shows the regional and total deposition of inhaled ribavirin aerosol in the respiratory tracts of persons in different age-groups from three months to 25 y.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3403994     DOI: 10.1093/infdis/158.2.443

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

Review 1.  Aerosol gene therapy.

Authors:  Ajay Gautam; J Clifford Waldrep; Charles L Densmore
Journal:  Mol Biotechnol       Date:  2003-01       Impact factor: 2.695

2.  Safety and pharmacokinetics of rimantadine small-particle aerosol.

Authors:  R L Atmar; S B Greenberg; J M Quarles; S Z Wilson; B Tyler; S Feldman; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice.

Authors:  J Conley; H Yang; T Wilson; K Blasetti; V Di Ninno; G Schnell; J P Wong
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of inhaled antimicrobials.

Authors:  Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

5.  A geometrical approach to the PKPD modelling of inhaled bronchodilators.

Authors:  Claudio Gaz; George Cremona; Simona Panunzi; Beverley Patterson; Andrea De Gaetano
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-17       Impact factor: 2.745

Review 6.  Aerosol treatment of respiratory viral disease.

Authors:  V Knight; B E Gilbert
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 7.  Antiviral therapy with small particle aerosols.

Authors:  V Knight; B Gilbert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

8.  Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice.

Authors:  B E Gilbert; P R Wyde; G Lopez-Berestein; S Z Wilson
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  MegaRibavirin aerosol for the treatment of influenza A virus infections in mice.

Authors:  Brian E Gilbert; Matthew T McLeay
Journal:  Antiviral Res       Date:  2008-02-04       Impact factor: 5.970

Review 10.  Gender effects in pharmacokinetics and pharmacodynamics.

Authors:  R Z Harris; L Z Benet; J B Schwartz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.